A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes for patients in earlier stages of this disease, a Peter Mac-led study has ...
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, causing more than 30,000 deaths in American men each year 1. Immunotherapy has largely been unsuccessful; both ...
-- Data presented at 100th Annual Meeting of the American Association for Cancer Research -- SEATTLE and DENVER, April 19 -- Researchers from Dendreon Corporation presented today data from its PROTECT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results